Autolus Therapeutics plc American Depositary Receipt (6A3A)
XMUN 
Summary
6A3A Chart
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
Autolus Therapeutics Q2 Earnings Call Highlights
Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier, as the company expanded treatment-center access and continued its commercial launch in the United States and United Kingdom.
Autolus Therapeutics plc American Depositary Receipt (6A3A) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Autolus Therapeutics plc American Depositary Receipt ever had a stock split?
Autolus Therapeutics plc American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Christian Martin Itin CEO | XMUN Exchange | US05280R1005 ISIN |
| GB Country | 752 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Autolus Therapeutics plc is a pioneering clinical-stage biopharmaceutical company dedicated to the development of innovative T cell therapies aimed at combating cancer and autoimmune diseases. Founded in 2014 and based in London, United Kingdom, the company has positioned itself at the forefront of cellular therapy with a focus on leveraging the body's immune system to fight malignancies and other serious ailments. Through its proprietary technology and advanced clinical programs, Autolus is pushing the boundaries of science to meet unmet medical needs in the oncology sector.
Products and Services
Autolus Therapeutics plc boasts a robust pipeline of clinical-stage programs, each targeting difficult-to-treat conditions through unique mechanisms. These include:
- Obecabtagene Autoleucel (AUTO1) - A CD19-targeting programmed T cell investigational therapy currently in a Phase 1b/2 clinical trial for the treatment of adult Acute Lymphoblastic Leukemia (ALL). This product exemplifies the company's commitment to addressing hematological malignancies with precision and innovation.
- AUTO1/22 - This therapy, in a Phase 1 clinical trial, targets pediatric patients suffering from relapsed or refractory ALL. AUTO1/22 showcases Autolus’ dedication to extending novel treatments to younger populations afflicted by aggressive forms of leukemia.
- AUTO4 - A targeted investigational therapy for the treatment of peripheral T-cell lymphoma, focusing on TRBC1 and TRBC2. AUTO4 represents a novel approach to treating this challenging form of cancer, emphasizing the specificity and potential of programmed T cell therapies.
- AUTO6NG - Targeting GD2, this investigational therapy is under development for the treatment of neuroblastoma, a rare type of cancer usually affecting children. AUTO6NG is a testament to Autolus’ efforts in pioneering treatments for pediatric oncology indications.
- AUTO8 - A promising candidate for the treatment of multiple myeloma, AUTO8 is part of Autolus’ diversified approach in tackling various hematological cancers with cutting-edge cellular therapy techniques.
- AUTO5 - Currently in preclinical development, AUTO5 is a TRBC2 programmed T cell product aimed at addressing peripheral T-cell lymphoma. This product highlights the ongoing research and development efforts at Autolus, underlining their long-term commitment to innovation in oncology.
Contact Information
